Efficacy of Anlotinib combined with S-1 as the second-line treatment for advanced soft tissue sarcoma

Asian J Surg. 2023 Feb;46(2):1050-1051. doi: 10.1016/j.asjsur.2022.07.128. Epub 2022 Aug 15.
No abstract available

Publication types

  • Letter

MeSH terms

  • Humans
  • Indoles / therapeutic use
  • Quinolines* / therapeutic use
  • Sarcoma* / drug therapy
  • Soft Tissue Neoplasms*

Substances

  • anlotinib
  • Indoles
  • Quinolines
  • S 1 (combination)